Ho-ho-ho! Gather around, my dear friends, for I have a tale from the land of medicine, a story as intriguing as the mystery of how I manage to deliver all those presents in one night. This narrative revolves around a magical procedure known as Middle Meningeal Artery Embolization (MMAE), a beacon of hope for those suffering from nonacute subdural hematomas (NASHs), a condition as bothersome as finding coal in your stocking.

In the years between 2019 and 2023, a group of wise elves, also known as medical researchers, embarked on a journey to understand the effectiveness of MMAE, especially for those on the naughty list of coagulopathy. Coagulopathy, my dear friends, is akin to having slippery ice on your roof, making it difficult for me to land my sleigh safely. It’s a condition where the blood’s ability to clot is impaired, and in this story, it’s caused by the use of certain potions like anticoagulation/antiplatelet agents or a spell of thrombocytopenia (a fancy term for a low platelet count).

Our diligent elves examined 537 patients who underwent this magical intervention, dividing them into groups based on whether they had coagulopathy or not. They meticulously collected data, as detailed as the list I check twice, including demographics, preprocedural characteristics, in-hospital course, and patient outcomes.

Through their analysis, a curious finding emerged, much like the surprise of finding a hidden present under the tree. Patients with coagulopathy were more likely to require a rescue mission, akin to me sending out my backup reindeer, than those without (9.9% vs 4.3% in unmatched analysis, and 12.6% vs 4.6% in matched analysis, both with a sprinkle of statistical significance). Specifically, those using antiplatelet agents, magical substances that prevent platelets from sticking together, had a higher chance of needing this rescue mission. And those with thrombocytopenia faced a greater risk of in-hospital mortality, a term as grim as a Christmas without cookies.

Yet, in the spirit of Christmas miracles, there were no differences in follow-up radiographic and other clinical outcomes between patients with and without coagulopathy. This tale teaches us that while MMAE is a promising gift for those with NASH, those with coagulopathy, especially those under the spell of antiplatelet agents or thrombocytopenia, may face greater challenges on their path to recovery.

So, as we close this chapter, let us remember the importance of understanding and preparing for the challenges that coagulopathy presents in the magical world of MMAE. And with that, I wish you all a merry journey back to your daily endeavors, filled with health, happiness, and a touch of Santa’s magic. Ho-ho-ho!